Structure Therapeutics (GPCR) Total Non-Current Liabilities (2022 - 2026)

Structure Therapeutics' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $60.2 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 44.62% year-over-year to $60.2 million; the TTM figure through Mar 2026 stood at $60.2 million (up 44.62% YoY), while the FY2025 annual figure was $66.9 million, up 75.18% from the prior year.
• Total Non-Current Liabilities was $60.2 million for Q1 2026 at Structure Therapeutics, down from $66.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $66.9 million in Q4 2025 to a low of $13.0 million in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $38.9 million across 5 years, with a median of $37.1 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities jumped 119.45% in 2023, then surged 33.74% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $13.0 million in 2022, then surged by 119.45% to $28.6 million in 2023, then soared by 33.74% to $38.2 million in 2024, then jumped by 75.18% to $66.9 million in 2025, then decreased by 10.06% to $60.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $60.2 million (Q1 2026), $66.9 million (Q4 2025), and $61.8 million (Q3 2025), per Business Quant data.